:CD8+T,

Xiaofang Lin1, Jianqiang Liu2, Ni Zhang3

  • 1Laboratory Department of Zengcheng Branch, Nanfang Hospital, Southern Medical University, Guangzhou, China.

PubMed
概括

这项研究揭示了CD8+ T细胞透是质瘤患者生存的关键预测因素. 一种使用特定基因和临床因素的新型诺米克图,有助于个性化的质瘤治疗决策.